Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 4/20 | 0.73 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.73 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.73 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819970 | 1.00 | SLC1A1 (0.73) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 | |
| SCHEMBL1818259 | 1.00 | SLC1A1 (0.73) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 | |
| SCHEMBL1821404 | 0.85 | SLC1A3 (0.53) | SLC1A1SLC1A3SLC1A2SLC7A5ALPI | |
| SCHEMBL1821403 | 0.85 | SLC1A3 (0.53) | SLC1A1SLC1A3SLC1A2SLC7A5ALPI | |
| SCHEMBL14674237 | 0.85 | SLC1A3 (0.53) | SLC1A1SLC1A3SLC1A2SLC7A5ALPI | |
| SCHEMBL13725557 | 0.85 | SLC1A1 (0.75) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 | |
| SCHEMBL1819024 | 0.85 | SLC1A1 (0.75) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 | |
| SCHEMBL13725911 | 0.85 | SLC1A1 (0.75) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 | |
| SCHEMBL2265548 | 0.84 | SLC1A1 (1.00) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 | |
| SCHEMBL133913 | 0.84 | SLC1A1 (1.00) | SLC1A1SLC1A3SLC1A2SLC7A5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-02-07 | — | — | US | claimed |
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | PIRAMAL IMAGING SA (CH) | 2013-02-07 | — | — | US | disclosed |
| EP-2501416-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | Piramal Imaging SA (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061154-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061154-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034497-A1 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES | GLUL, GCG, GLS | SLC1A1 67/4885SLC1A3 63/4885SLC1A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.